By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vaccine developer Affiris will use Probiogen's Human Artificial Lymph Node Technology (HuALN) as an analytical tool to find targets for its Affitome vaccination project, Affiris said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.